Latest news with #RegulationNo.596
Yahoo
3 days ago
- Business
- Yahoo
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company's managerial employees and their closely associated persons. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines®. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit and follow us on LinkedIn and Marisol Peron, Senior Vice President, Global Communications & Corporate AffairsT: +1 609 524 0065; E: mmp@ Andrew Carlsen, Vice President, Head of Investor RelationsT: +45 3377 9558; E: acn@ This Company Announcement contains forward looking statements. The words 'believe,' 'expect,' 'anticipate,' 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. Company Announcement no. 34CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A/SCarl Jacobsens Vej 302500 Valby Denmark Attachment 170625_CA34_Managerial Employee Transactions_FINALSign in to access your portfolio
Yahoo
21-05-2025
- Business
- Yahoo
NKT initiates share buyback to meet obligations for share-based incentive programmes for employees
Company Announcement 21 May 2025Announcement No. 17 NKT initiates share buyback to meet obligations for share-based incentive programmes for employees Share based incentivesThe Board of Directors of NKT A/S has decided to exercise the authority to buy back shares granted by the Annual General Meeting on 25 March 2021. The authorisation is valid in the period until 31 March 2026, and the Board of Directors is authorised to arrange for acquisition of the Company's own shares up to a nominal value of 10% of the share capital. The share buyback is to meet obligations relating to the Company's share-based incentive programmes for employees. Employee share programmeAt the Annual General Meeting and in Company Announcement No. 14 dated March 19, 2025, NKT announced the anticipated launch of an employee share programme in June. NKT now confirms the launch of the employee share programme in June. The purpose of the share buyback programme is to fulfill the obligations arising from this initiative. The share buyback programme will run from 22 May 2025 and end no later than 20 June 2025. During this period, NKT A/S will buy its own shares up to a maximum of 268,949 shares in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour-rules. Terms NKT A/S is required to retain a lead manager who is to make its own trading decisions independently of and without influence from the Company and execute the share buyback programme within the announced limits. NKT A/S has designated Nordea Denmark, Filial af Nordea Bank Abp, Finland as its lead manager for the share buyback programme. Under the share buyback programme, NKT A/S may repurchase up to 268,949 shares, corresponding to 0.50% of the current share capital of NKT A/S, for an amount up to maximum DKK 175m. No shares may be bought back at a price exceeding the higher of (i) the share price of the latest independent trade and (ii) the highest current independent bid at Nasdaq Copenhagen at the time of trading in compliance with the authority. The maximum number of NKT A/S shares that may be purchased on each business day may not exceed 25% of the average daily trading volume of NKT A/S shares on Nasdaq Copenhagen during the 20 trading days preceding the date of purchase. Contact InvestorsJacob Johansen, Head of Investor Relations+45 2169 3591 / Pelle Fischer-Nielsen, External Communications Lead, +45 2223 5870 / Attachment NKT initiates share buyback
